| Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): First Real-World Evidence of NSCLC Stage II and III in Germany - AIO-TRK-0315 |
|
|
| Oncol Res Treat 45 (suppl. 3: 5-284): 148 | abstract 135 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.karger.com/Article/Pdf/521004 |
|
|
| Effectiveness of nivolumab in patients with advanced non-small cell lung cancer in real-life practice in France and Germany: analysis of the ESME-AMLC and CRISP cohorts. |
|
|
| Cancers 14(24): 6148 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.mdpi.com/2072-6694/14/24/6148 |
|
|
| Patient-reported outcomes in patients with locally advanced or metastatic NSCLC in Germany before and during the COVID-19 pandemic – Data from the prospective CRISP Registry (AIO-TRK-0315). |
|
|
| Oncol Res Treat 45 (suppl. 2: 11-346): 127; poster P394 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.karger.com/Article/abstract/526456 |
|
|
| Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-World Evidence of NSCLC patients treated with radiochemotherapy in Germany AIO-TRK-0315. |
|
|
| Oncol Res Treat 45 (suppl. 2: 11-346): 269-70; Vortrag V899 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.karger.com/Article/abstract/526456 |
|
|
| Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315. |
|
|
| Zentralbl Chir 147 (S 01): 47-8 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-1754182 |
|
|
| CRISP: First Real-World Evidence of NSCLC Stage I,II and III in Germany - AIO-TRK-0315. |
|
|
| Journal of Thoracic Oncology 17 (9 supplement): 280 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.jtho.2022.07.477 |
|
|
| EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315). |
|
|
| Ann Oncol 33 (S2): 54-5 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.annonc.2022.02.058 |
|
|
| Impact of immune checkpoint Inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life pratice in patients initiating treatment between 2015 And 2018 In France And Germany. |
|
|
| Lung Cancer 172: 65-74 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.lungcan.2022.08.001 |
|
|
| P1.15-05 Nintedanib in Combination with Nivolumab in Pretreated Patients with Advanced Adenocarcinoma of the Lung (AIO-TRK-0117 Phase IB/II Trial) |
|
|
| Journal of Thoracic Oncology 17 (9 supplement): 121 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| www.jto.org/article/S1556-0864(22)00542-1/fulltext |
|
|
| Pembrolizumab Maintenance in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sNSCLC) - AIO-TRK-0115/PRIMUS |
|
|
| Journal of Thoracic Oncology 17 (9 supplement): 366-7 |
|
2022 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.jtho.2022.07.629 |
|
|
